Clinical trials: Tetanus-diphtheria-acellular Pertussis (Tdap)
- Condition Tetanus-diphtheria-acellular Pertussis (Tdap)
- Funder type Industry (pharma, biotech, devices)
Diphtheria, Tetanus
A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine
This study will evaluate the safety and immune response to GlaxoSmithKline Tdap vaccine compared to licensed Td vaccine when used as a booster in healthy adolescents (10-18 years of age).
- Conditions
- Diphtheria, Tetanus, Acellular Pertussis
- Trial name
- NCT00109330
- Testing
- Combined diphtheria, tetanus, acellular pertussis vaccine
- Where
- 44 sites in United States
- Volunteers
- 4,116 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Disease, Meningococcal Meningitis
Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years
Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years
- Trial name
- NCT00329901
- Testing
- Meningococcal ACWY conjugate vaccine (MenACWY-CRM), Combined tetanus, reduced diphtheria and acellular pertussis vaccine (Tdap)
- Where
- 14 sites in Italy
- Volunteers
- 1,072 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Acellular Pertussis, Tetanus
Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9
The purpose of this study is to evaluate the persistence of antibodies against all the vaccine antigens 1, 3, 5 and 9 years after an initial vaccination with Tdap, and also to assess immunogenicity and safety of another dose of…
- Conditions
- Acellular Pertussis, Tetanus, Diphtheria
- Trial name
- NCT00489970
- Testing
- Taking of blood samples, Boostrix, Adacel
- Where
- 37 sites in United States
- Volunteers
- 1,954 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tetanus, Acellular Pertussis
Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines
The aims of this trial are to demonstrate the consistency of three manufacturing lots of GSK Biologicals' DTaP-IPV candidate vaccine in terms of immunogenicity and to evaluate the non-inferiority of GSK Biologicals' DTaP-IPV…
- Conditions
- Tetanus, Acellular Pertussis, Diphtheria
- Trial name
- NCT00148941
- Testing
- SB213503 lot 1, SB213503 lot 2, SB213503 lot 3
- Where
- 24 sites in United States
- Volunteers
- 4,209 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pertussis Whooping Cough
Immunogenicity of a Combined Diphtheria-Tetanus-recombinant Acellular Pertussis (DTaP) Vaccine in Healthy Toddlers
Recombinant acellular pertussis vaccines containing genetically detoxified Pertussis Toxin (PTgen) have been used for booster immunisation in children, adolescents and adults including pregnant women in Thailand.
- Trial name
- NCT07213089
- Testing
- Combined Diphtheria-Tetanus-recombinant acellular pertussis (DTaP) vaccine, Licensed DTaP
- Where
- 3 sites in Thailand
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- BioNet-Asia Co., Ltd.
Acellular Pertussis, Diphtheria
Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunogenicity and Safety to Children and Adolescents Previously Vaccinated With Five Doses of an Acellular Pertussis-containing Vaccine.
The aims of this study are to evaluate the safety and immunogenicity of a booster dose of GSK Biological's candidate Tdap vaccine containing 0.3 mg Al when administered to healthy school children and adolescents (9-13 years of…
- Conditions
- Acellular Pertussis, Diphtheria, Tetanus
- Trial name
- NCT00263679
- Testing
- Prophylaxis: Diphtheria, tetanus and pertussis
- Where
- 13 sites in Germany
- Volunteers
- 321 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tetanus, Diphtheria
Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old
The aim of the study is to generate additional safety and immunogenicity data to support the registration of the product in Japan.
- Conditions
- Tetanus, Diphtheria, Pertussis
- Trial name
- NCT02089347
- Testing
- Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, Diphtheria and Tetanus toxoids adsorbed
- Where
- 19 sites in Japan
- Volunteers
- 534 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pertussis
Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1)
The purpose of this study is to evaluate the persistence of immune response against the three pertussis antigens (anti- pertussis toxoid (PT), anti-filamentous hemagglutinin (FHA) and anti-pertactin (PRN)) in subjects who…
- Trial name
- NCT02382913
- Testing
- aP booster, TdaP booster, Licensed TdaP booster (Boostrix®)
- Where
- Belgium
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Novartis
Meningitis, Meningococcemia
Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine
The purpose of this study was to evaluate the immunogenicity and safety of the concomitant administration of Menactra® vaccine and Tdap vaccine in adolescents aged 11 to 17 years.
- Conditions
- Meningitis, Meningococcemia, Pertussis, Tetanus
- Trial name
- NCT00777257
- Testing
- T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap
- Where
- 20 sites in United States
- Volunteers
- 1,345 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Tetanus Immunisation (Healthy Volunteers), Diphtheria Immunisation (Healthy Volunteers)
A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada
The primary objectives of this study are: To describe the safety profile of each of the investigational vaccine formulations for all participants To describe the humoral and cell-mediated immune responses to all of the…
- Conditions
- Tetanus Immunisation (Healthy Volunteers), Diphtheria Immunisation (Healthy Volunteers), Pertussis Immunisation (Healthy Volunteers)
- Trial name
- NCT03958799
- Testing
- Investigational Tdap vaccine Formulation B, Investigational Tdap vaccine Formulation C, Investigational Tdap vaccine Formulation A
- Where
- 5 sites in Canada
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Respiratory Tract Infection
A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS
This phase 2b study will evaluate safety, tolerability, and immunogenicity of an RSV vaccine when given together with Tdap in approximately 710 healthy nonpregnant women 18 through 49 years of age.
- Trial name
- NCT04071158
- Testing
- RSV Vaccine, Tdap
- Where
- 16 sites in United States
- Volunteers
- 713 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pertussis, Tetanus
Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose
The purpose of this study is to collect additional immunogenicity and safety data on re-dosing with Tdap vaccine (ADACEL®) in a continuing effort to address the public health need to establish broader population immunity against…
- Conditions
- Pertussis, Tetanus, Diphtheria
- Trial name
- NCT00712959
- Testing
- Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)
- Where
- 7 sites in Canada
- Volunteers
- 769 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Healthy Subjects
Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants
Subjects will be randomly assigned to 1 of 3 groups to receive the following vaccines: Group 1: 13-valent pneumococcal conjugate vaccine (13vPnC) and diphtheria, tetanus, and acellular pertussis vaccine (DTaP), Group 2: 7-valent…
- Trial name
- NCT01200368
- Testing
- 13-valent pneumococcal conjugate vaccine (13vPnC), diphtheria, tetanus, and acellular pertussis vaccine (DTaP), 7-valent pneumococcal conjugate vaccine (7vPnC)
- Where
- 32 sites in Japan
- Volunteers
- 551 people
- Sponsor
- Pfizer
Healthy Subjects
A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants.
Subjects will be randomly assigned to 1 of 2 groups to receive the following vaccines: Group 1: 7-valent pneumococcal conjugate vaccine (7vPnC) and diphtheria, tetanus, and accelular pertussis vaccine (DTaP), Group 2: DTaP alone.
- Trial name
- NCT01250756
- Testing
- 7-pneumococcal conjugate vaccine (7vPnC), diphtheria, tetanus, and acellular pertussis vaccine (DTaP), DTaP
- Where
- 18 sites in Japan
- Volunteers
- 321 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diphtheria, Acellular Pertussis
Post Market Surveillance for Infanrix™
The purpose of this study was to investigate the following questions through post-marketing surveillance: Unknown/Unexpected adverse events and the serious adverse events.
- Conditions
- Diphtheria, Acellular Pertussis, Tetanus
- Trial name
- NCT00908115
- Testing
- GSK Biologicals' Infanrix™
- Where
- South Korea
- Volunteers
- 1,258 people
- Sponsor
- GlaxoSmithKline
Whooping Cough
The Safety of Boostrix Following Routine Immunization of Pregnant Women
The purpose of this study was to assess the safety of Boostrix administered on or after the first day of the 27th week of pregnancy by conducting a post-marketing study that provided safety information to the public and…
- Trial name
- NCT03463577
- Testing
- Safety assessment following routine immunization with Boostrix
- Where
- United States
- Volunteers
- 65,783 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tetanus, Diphtheria
Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine
The purpose of this study is to evaluate safety of GC3111 and to describe immunogenicity of a single dose of GC3111 versus Boostrix® vaccine among healthy adults in 19 to <65 years of age.
- Conditions
- Tetanus, Diphtheria, Whooping Cough
- Trial name
- NCT02813486
- Testing
- Biological: GC3111 vaccine, Biological: Boostrix® vaccine
- Where
- 5 sites in South Korea
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Pertussis (Whooping Cough), Tetanus
Safety Monitoring of Boostagen® Vaccine in Thailand
This study is designed to monitor the safety of Boostagen® after it has been approved for use in Thailand. The study follows people who receive the vaccine in routine medical practice to identify and record any side effects.
- Conditions
- Pertussis (Whooping Cough), Tetanus, Diphtheria
- Trial name
- BOOSTg001 (NCT07444502)
- Where
- Thailand
- Volunteers
- 10,727 people, healthy volunteers welcome
- Sponsor
- BioNet-Asia Co., Ltd.
Diphtheria, Acellular Pertussis
Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety
The aims of this study are to compare the immunogenicity and safety of the GSK Biologicals' combined DTaP-IPV vaccine with separate administration of DTaP and IPV vaccines, when administered as a fifth dose of acellular pertussis…
- Conditions
- Diphtheria, Acellular Pertussis, Tetanus
- Trial name
- NCT00263692
- Testing
- Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3
- Where
- 15 sites in United States
- Volunteers
- 401 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline